Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix

Sponsor
University of Michigan (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05819515
Collaborator
(none)
36
1
2
16.1
2.2

Study Details

Study Description

Brief Summary

The study aims to test the non-inferiority of an Allogenic Dermal Matrix with Platelet-Rich Fibrin for treatment of gingival recessions in comparison to the Connective Tissue Graft.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Tunneled coronally advanced flap
N/A

Detailed Description

Currently the Connective Tissue Graft (CTG) is referred to as the gold standard in terms of the grafting material for the treatment of gingival recession defects. This study test the non-inferiority of the Allogenic Dermal Matrix (ADM) with Platelet-Rich Fibrin (PRF) to that of the CTG, in terms of the amount of root coverage obtained after the procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix, Compared to the Connective Tissue Graft: A Parallel-arm, Randomized, Controlled, Assessor-blind, Non-inferiority Clinical Trial
Anticipated Study Start Date :
Apr 29, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Connective Tissue Graft

A connective tissue graft from the patient's palate will be used

Procedure: Tunneled coronally advanced flap
Describes the flap design for both treatment arms

Experimental: Allogenic Dermal Matrix with Platelet-Rich Fibrin

An allogenic dermal matrix with the patient's platelet-rich fibrin will be used

Procedure: Tunneled coronally advanced flap
Describes the flap design for both treatment arms

Outcome Measures

Primary Outcome Measures

  1. Mean root coverage (mRC) [Assessed at 6 months]

    Measured as a percentage of the total baseline recession defect that coverage was obtained at.

  2. Complete root coverage (CRC) [Assessed at 6 months]

    Measured as a percentage of total treated sites, that obtained a full coverage of the recession defect

  3. Keratinized tissue (KT) gain [Assessed at 6 months]

    Measured in mm

  4. Gingival thickness (GT) gain [Assessed at 6 months]

    Measured in mm

  5. Patient-reported outcomes (PROMs) [Measured from the day of the procedure up to a maximum of 1 month]

    In terms of pain/discomfort at the palatal donor site or patient's arm. Measured using a scale from 0 (lowest) to 10 (highest).

  6. Duration of surgical procedure [During surgery]

    Including the length of surgical procedure, drawing of blood, and preparation of PRF, harvesting of the autogenous CTG. Measured in minutes.

Secondary Outcome Measures

  1. Professionally evaluated esthetic score [Assessed at 6 months]

    Assessed using the Root coverage Esthetic Score (RES) system (from 0 lowest, to 10 highest)

  2. Soft tissue volume changes over time [Changes of from baseline (prior to treatment) compared with 3 and 6 months]

    Assessed using 3D scanner imaging in the units of mm

  3. Soft tissue volume changes over time [Measured throughout the study to assess changes from immediate post-op (right after the completion of surgical appointment) until the final recall at 6 months]

    Assessed using dental ultrasonography in the units of mm

  4. Soft tissue blood flow changes over time [Measured throughout the study to assess changes from immediate post-op (right after the completion of surgical appointment) until the final recall at 6 months]

    Assessed and quantified using dental ultrasonography

  5. Patient-reported esthetics [Measured at baseline and at 6 months, and compared between these time points to provide subjective esthetic results]

    Based on a visual analogue scale (VAS), measured as numbers from 0 (lowest) to 10 (highest).

  6. Patient-reported satisfaction [Measured at 6 months to provide the satisfaction score in VAS scale]

    Based on a visual analogue scale (VAS), measured as numbers from 0 (lowest) to 10 (highest).

  7. Patient-reported post-operative pain as measured with a mobile application [From the day of the procedure until 1 month after the surgical time point]

    Measured using a mobile application at the recession grafted site, the donor site on the palate, and the donor site for the venopuncture.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Periodontally and systemically healthy adults

  • Full-mouth plaque score and full-mouth bleeding score ≤ 20%

  • Presence of at least one 3 mm or deeper gingival recession, with at least 1.5 mm of Keratinized tissue, and 1 mm of gingival thickness) requiring surgical intervention for root coverage

  • No interproximal attachment/bone loss

  • No prior experience of root coverage procedures within the last 1 year

  • The patient must be able to perform good oral hygiene

Exclusion Criteria:
  • Contraindications for undergoing periodontal surgery

  • Teeth with more than Grade II mobility, or furcation involvement of Class III

  • Patients pregnant or attempting to get pregnant (self-reported), or nursing women

  • Untreated/active periodontitis, or other untreated acute infections at the surgical site

  • Untreated malignancies at the surgical site

  • Persistence of uncorrected gingival trauma from traumatic toothbrushing

  • Presence of severe tooth malposition, rotation or clinically significant super-eruption

  • Self-reported current smoking more than 10 cigarettes/day or pipe or cigar smoking, or active tobacco chewing, or chronic vaping

  • Patients with any known history of blood disorders or complications such as abnormal concentration of thrombin and factor XIII in plasma, or hemophilia

  • Patients with significant co-morbidities, such as obesity, uncontrolled diabetes, immunosuppression, severe endocrine-induced bone diseases, signs of malnourishment, those receiving immunosuppressive therapy, poor tissue oxygenation or perfusion, and pre- or post-operative radiation

  • Patients with known sensitivity to Polysorbate 20, Cefoxitin, Lincomycin, polymyxin B, Vancomycin

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Michigan - Ann Arbor Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: Hom-Lay Wang, DDS MSD PhD, University of Michigan
  • Principal Investigator: Shayan Barootchi, DMD, MS, University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hom-Lay Wang, DDS, MSD, Ph D, Professor, University of Michigan
ClinicalTrials.gov Identifier:
NCT05819515
Other Study ID Numbers:
  • HUM00214311
First Posted:
Apr 19, 2023
Last Update Posted:
Apr 19, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2023